Simon Ducharme testing cutting-edge gene therapy that could slow Frontotemporal Dementia
Published on: 2023-12-12
January 8, 2024
Dr. Simon Ducharme is featured in the McGill Reporter for his participation in Phase I clinical trial testing this potentially groundbreaking treatment that hopes to slow or stop an inherited form of Frontotemporal Dementia (FTD). The study is the first gene therapy trial for dementia conducted in Canada.
“The idea is that even if the disease is present the progression could be stopped in its tracks. You could have a patient who has progressed but who would benefit by maintaining their quality of life without further deterioration. One day, if treatments like this one are successful, the treatment might extend to those with the mutation prior to symptom onset to spare them from developing this condition.”
– Dr. Simon Ducharme
Source: McGill Reporter